trending Market Intelligence /marketintelligence/en/news-insights/trending/yh199cxd9jecxkgqmju_xa2 content esgSubNav
In This List

Merck's cancer vaccine secures US FDA priority review for extended use

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism


Merck's cancer vaccine secures US FDA priority review for extended use

The U.S. Food and Drug Administration granted priority review to Merck & Co. Inc.'s application for human papillomavirus vaccine Gardasil 9 for preventing certain cancers and diseases in men and women ages 27 to 45.

The Kenilworth, N.J.-based company said its biologics license application is seeking approval for Gardasil 9 for preventing certain cancers and diseases caused by the nine human papillomavirus, or HPV, types covered by the vaccine.

Merck said the the U.S. regulator will take a decision on the application by October 6.

Gardasil 9, which had sales of about $660 million in the first quarter of 2018, is approved in the U.S. for females ages 9 to 26 years to prevent cervical, vulvar, vaginal and anal cancers and for males ages 9 to 26 to prevent anal cancer caused by certain HPV types.